Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Authors:
- C Funck-BrentanoCFC Funck-Brentano
- J TurgeonJTJ Turgeon
- R L WoosleyRWR L Woosley
- D M RodenDRD M Roden
- 1 April 1989
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 249 (1) , 134-142
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Electrophysiology of O-Demethyl Encainide in a Canine Model of Sustained Ventricular TachycardiaJournal of Cardiovascular Pharmacology, 1984
- Influence of genetic polymorphism on the metabolism and disposition of encainide in man.The Journal of Pharmacology and Experimental Therapeutics, 1984
- Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.Journal of Clinical Investigation, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Antiarrhythmic activity of the O-demethyl metabolite of encainide.The Journal of Pharmacology and Experimental Therapeutics, 1982
- Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers.The Journal of Pharmacology and Experimental Therapeutics, 1982
- Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.Circulation, 1981
- Total Suppression of Ventricular Arrhythmias by EncainideNew England Journal of Medicine, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977